Why have this therapy in China specifically?

China offers high-quality somatropin produced by domestic manufacturers that meet international standards, at significantly lower costs—typically $5,000–$12,000 per year compared to $20,000–$40,000 in the U.S. or Europe. Chinese endocrinologists have extensive experience with high patient volumes, and top-tier hospitals provide advanced diagnostic tools like MRI and dynamic hormone testing. This combination of affordability, expertise, and technology makes China a competitive destination for growth hormone therapy.